In Situ Electrophysiological Examination of Pancreatic α Cells in the Streptozotocin-Induced Diabetes Model Revealing the Cellular Basis of Glucagon Hypersecretion

Ya-Chi Huang, Marjan S. Rupnik, Negar Karimian, Pedro L. Herrera, Patrick Gilon, Zhong-Ping Feng and Herbert Y. Gaisano

Early-stage type 1 diabetes (T1D) exhibits hyperglucagonemia by undefined cellular mechanisms. Here we characterized α-cell voltage-gated ion channels in a streptozotocin (STZ)-induced diabetes model that lead to increased glucagon secretion mimicking T1D. GYY mice expressing enhanced yellow fluorescence protein in α cells were used to identify α cells within pancreas slices. Mice treated with low-dose STZ exhibited hyperglucagonemia, hyperglycemia, and glucose intolerance, with 71% reduction of β-cell mass. Although α-cell mass of STZ-treated mice remained unchanged, total pancreatic glucagon content was elevated, coinciding with increase in size of glucagon granules. Pancreatic tissue slices enabled in situ examination of α-cell electrophysiology. α cells of STZ-treated mice exhibited the following: 1) increased exocytosis (serial depolarization-induced capacitance), 2) enhanced voltage-gated Na* current density, 3) reduced voltage-gated K* current density, and 4) increased action potential (AP) amplitude and firing frequency. Hyperglucagonemia in STZ-induced diabetes is thus likely due to increased glucagon content arising from enlarged glucagon granules and increased AP firing frequency and amplitude coinciding with enhanced Na* and reduced K* currents. These alterations may prime α cells in STZ-treated mice for more glucagon release per cell in response to low glucose stimulation. Thus, our study provides the first insight that STZ treatment sensitizes release mechanisms of α cells.

Glucagon promotes glucose mobilization in liver through glycogenolysis and gluconeogenesis (1,2). Low blood glucose level normally triggers glucagon release from pancreatic α cells to prevent hypoglycemia caused by physical activity or excessive insulin actions (1–3). In T1D, glucagon secretion becomes dysregulated. In early stage of T1D, α cells hypersecrete (1,2,4), causing excessive release of glucose, resulting in hyperglycemia and leading to long-term complications (blindness and organ failure). As diabetes progresses, α cells suffer from “hypoglycemicblindness,” becoming sluggish in response to low glucose, exacerbating life-threatening acute hypoglycemic episodes (3,5). No effective treatment has been developed to regulate glucagon secretion to combat hypoglycemic attacks.

Despite the importance of α cells in health and diabetes, this islet cell type has been relatively less studied than β cells. The primary reason for the slower investigation of α cells has been the low-yield isolation (~20% of islet cells) and unreliable and inefficient identification of α cells when using conventional strategies of islet isolation and dispersion. We have recently developed the pancreas slice preparation to effectively circumvent these long-standing technical difficulties in assessing α-cell function (6), allowing reliable, efficient, and immediate examination of living α cells. Islet architecture within slices is well preserved, wherein α cells are retained in their celluoso-social environment, unperturbed by enzymatic and mechanical stresses inherent in conventional α-cell isolation procedures. α cells in pancreas slices were directly assessed via patch pipette. We demonstrated that every single α cell examined exhibited all the classical electrophysiological features of mouse α cells (6).

Although we and others have characterized normal α-cell biology in healthy rodent and human islets in some detail (6,7), disruptions of α-cell biology caused by T1D have been minimally investigated. This is because T1D islets shrink in size and lose their compact islet architecture from immune-mediated β-cell ablation. This has rendered isolation of α cells from immunologically damaged islets by conventional methods technically unfeasible, thus hampering investigation of the α cell in its native disease state. We have now surmounted this problem by using the pancreas slice preparation in mice administered streptozotocin (STZ), which creates a state that in several aspects resembles T1D (8,9). We used GhuCre-ROSA26EYFP (GYY) mice, which express enhanced yellow fluorescence protein (EYFP) in α cells (10), to precisely identify α cells within the much-reduced islet mass in the pancreas slice. α Cells within pancreas slices can be directly assessed by standard patch-clamp technique. Our combinatorial strategy allowed efficient investigation of α cells in disease (T1D) states that was not previously possible. We elucidated the alterations in ion channel properties in α cells that contribute to the intensified action potential (AP) firing and increased amplitude, which we postulate to lead to the clinically observed systemic hyperglucagonemia in early stage of T1D.

RESEARCH DESIGN AND METHODS
Animal care and all procedures were approved by the Institutional Animal Care and Use Committee of the University of Toronto. GYY mice were previously described by P.G. (10). GYY mice (16–20 weeks old) used in this study were of similar age at which NOD mice develop overt diabetes (11) and have fully developed pancreas with adult-size islets to ensure that islet shrinkage from STZ-induced β-cell death (9) remains visible within the pancreas slices.

From the 1Institute of Medical Science, University of Toronto, Toronto, Ontario, Canada; 2Faculty of Medicine, Institute of Physiology/CIPKEBIP, University of Maribor, Maribor, Slovenia; 3Cell Physiology & Metabolism, University of Geneva, Geneva, Switzerland; 4Pôle d’Endocrinologie, Diabète et Nutrition, Université Catholique de Louvain, Brussels, Belgium; and 5Physiology and Medicine, University of Toronto, Toronto, Ontario, Canada.

Corresponding author: Herbert Y. Gaisano, herbert.gaisano@utoronto.ca.

Received 11 June 2011 and accepted 28 July 2012.

© 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.↩

Diabetes Publish Ahead of Print, published online October 5, 2012
FIG. 1. STZ-induced diabetes in GYY mice. Time courses of fasting (A) and re-fed (B) blood glucose levels, fasting (C) and re-fed (D) plasma glucagon levels, and body weight (E). The measurements were made periodically from the control and STZ-treated mice before (0 week) and over the course of 4 weeks after the first day of STZ injection. All data are plotted as means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (control mice, n = 10; STZ-treated mice, n = 12). F: Time course of IPGTT. Blood glucose levels were measured from the control (n = 10) or STZ-treated (n = 16) mice 4 weeks postinjection ***P < 0.001). Conc., concentration.
FIG. 2. Comparison of islet morphology between control and STZ-treated GYY mice. A and B: Representative images of islets of control (A) and STZ-treated (B) GYY mice embedded in pancreas slices. Images in the right panels (Ai, Ai', Bi, and Bi') were magnified from the inset white boxes in the left panels (Ai, Aii, Bi, and Bii'). In control islets (A), α cells expressing EYFP (in the cytosol) stained with glucagon located in the periphery of the cells (Ai and Aii': red, glucagon; yellow, EYFP). Insulin-labeled β cells (Ai and Aii': red, insulin; yellow, EYFP) are abundant in the islet core. In STZ-treated mice, the majority of β cells were ablated by STZ treatment (Bi and Bi': red, insulin; yellow, EYFP) with α cells redistributed to the islet core (Bi and Bi': red, glucagon; yellow, EYFP). Similar to control islets, these α cells in STZ-treated mice expressing EYFP also exhibit glucagon staining in the periphery of the cells. (n = 5 mice in each group.) C and D: Total pancreatic β-cell (C) and α-cell (D) masses in the control and STZ groups determined 4 weeks after injection (n = 5 mice in each group). E and F: Total pancreatic insulin (E) and glucagon (F) content in the control and STZ groups measured at 4 weeks after STZ treatment. (⁎P < 0.05, ⁎⁎0.01, and ⁎⁎⁎0.001, respectively; n = 5 mice in each group.) G: Representative images of pancreas slice prepared from control (a and b) and STZ (c and d) mice viewed under bright-field (a and c) or EYFP-specific (b and d) filter. In both islets, a patch pipette (white arrow) is shown approaching a cell on the islet edge, which expresses EYFP. (A high-quality digital representation of this figure is available in the online issue.)
Diabetes induction. STZ (Biosept, Burlington, Ontario, Canada) dissolved in sodium citrate buffer at a single daily dose of 40 mg/kg body mass was injected intraperitoneally into mice for 5 consecutive days and maintained for 4 weeks to allow animals to reach and surpass the peak incidence of β-cell apoptosis (9). Control mice were fed with citrate buffer. All mice were killed by cervical dislocation after the 4th week of STZ treatment for further experimentation.

For the intraperitoneal glucose tolerance test (IPGTT), 1.5 g glucose/kg body weight i.p. was injected into overnight-fasted (16 h) mice; blood glucose (glucometer, LifeScan, Burnaby, British Columbia, Canada) and glucagon were measured as indicated. For refed levels, mice fasted overnight (for fasting levels) were then given standard normal chow for 3 h. Blood samples were collected from femoral vein and loaded into capillary tubes coated with Kalium-EDTA (Microvette CB 3000; Sarstedt, Montreal, Quebec City, Canada); plasma was separated by centrifugation (10,000g, 10 min), and glucagon was assayed by RIA (Millipore, Etobicoke, Ontario, Canada).

Pancreatic α- and β-cell mass and insulin and glucagon content measurements. Islet cell mass was measured as previously described (12). Briefly, resected pancreata were fixed in 4% paraformaldehyde, embedded in paraffin, and thinly sectioned (5 μm thin) and then dewaxed, rehydrated, and immunostained with rabbit polyclonal anti-insulin (1:200; Biomeda) or anti-glucagon (1:150; Vision Biosystems) antibodies and counterstained with hematoxin-eosin. Slides were digitized on a bright-field scanner (×20 magnification), and quantitative analysis of stained areas was performed with ImageScope software (Aperio Technologies, Vista, CA) using a positive-pixel count algorithm.

For hormone content measurements, isolated pancreata were placed in acid-ethanol mixture (1.5% HCl 70% ETOH), incubated overnight (−20°C), and then homogenized; the tissue levels of insulin and glucagon extracted by centrifugation (5,000g, 15 min) were then determined by RIA kits (Millipore) and normalized to total pancreatic protein content.

Pancreas slice preparation. Pancreatic tissue slices were prepared as we recently reported (6). Electrophysiology was conducted an hour after preparation and completed within 5 h.

Immunofluorescence and electron microscopy. Immunofluorescence microscopy was performed as described in our recent report (6) with the following primary antibodies (1:100, 3 h): mouse anti-glucagon or anti-insulin (Sigma) or anti-somatostatin (GeneTex, Irvine, CA). Electron microscopy was performed as we previously described (13). Glucagon granules (thus a cell identified by the typical appearance (large black dense core with thin halo) (14,15).

Pancreatic α- and β-cell mass between STZ and control mice (Fig. 2A and B). Total pancreatic α- and β-cell masses were determined by immunohistochemical quantification of insulin- and glucagon-positive staining areas (see RESEARCH DESIGN AND METHODS), normalized to entire pancreas cross-sectional tissue area; the resulting values were then multiplied by the wet pancreas weight of each mouse. Mean pancreas wet weights were similar (control 0.216 ± 0.006 g vs. STZ mice 0.251 ± 0.05 g; P = 0.43). The relative ratio of α cell to total pancreatic tissue area was also similar (control 0.0029 ± 0.0005 vs. STZ 0.0024 ± 0.0002; P = 0.36). However, the ratio of β cell to total pancreatic tissue area was reduced in STZ-treated mice (control 0.0152 ± 0.0017 vs. STZ 0.0048 ± 0.0006; P = 0.0005). STZ treatment reduced β-cell mass by 71% (Fig. 2C), but there was no difference in α-cell mass between STZ and control mice (Fig. 2D).

Total pancreatic glucagon and insulin content normalized to the total protein content of each pancreas showed that STZ mice had increased mean pancreatic glucagon content (STZ mice 440,747 ± 55,473 pg vs. control 103,398 ± 5,999 pg; n = 5 mice/group, P = 0.0002) and reduced mean insulin content (STZ mice 4,091 ± 564 ng vs. control 6,518 ± 5579 ng; P = 0.00003). Mean pancreatic protein content was similar (STZ mice 23,590 ± 470 μg vs. control 22,621 ± 473 μg; P = 0.18). In the STZ-treated mice group, total pancreatic insulin content per protein content was severely reduced because of β-cell destruction (Fig. 2E) (control 3.02 ± 0.22 ng/μg vs. STZ 0.17 ± 0.02 ng/μg). Surprisingly, total pancreatic glucagon content per protein content in the STZ group was remarkably elevated to fourfold higher than in control mice (Fig. 2F) (control 4.59 ± 0.32 vs. STZ 18.71 ± 2.19 μg/μg).

RESULTS

STZ induction of diabetes in GYY mice. Fasting blood glucose level in STZ-treated GYY mice increased at 2 weeks (Fig. 1A) and refed blood glucose level at 1 week (Fig. 1B) posttreatment. Fasting (Fig. 1C) and refed (Fig. 1D) plasma glucagon levels rose to abnormal levels at 2 weeks and 1 week post-STZ treatment, respectively. The increased plasma glucagon levels (Fig. 1C and D) contributed in part to the observed hyperglycemia (Fig. 1A and B) in STZ-treated GYY mice. At 4 weeks post-STZ treatment, the mice showed the stable diabetes phenotype characterized as high and sustained fasting blood glucose (Fig. 1A) (control 6.1 ± 0.3 mmol/L, n = 10, vs. STZ 11.7 ± 1.7 mmol/L, n = 12), refed blood glucose (Fig. 1B) (control 10.1 ± 0.5 mmol/L vs. STZ 28.7 ± 1.5 mmol/L), fasting plasma glucagon (Fig. 1C) (control 70.3 ± 4.3 pg/mL vs. STZ 120.9 ± 24.2 pg/mL), and fed plasma glucagon (Fig. 1D) (control 113.9 ± 31.8 pg/mL vs. STZ 220.1 ± 32.7 pg/mL) compared with the controls. The STZ-GYY mice also experienced mild weight loss (Fig. 1E) and developed glucose intolerance (IPGTT) (Fig. 1F) at 4 weeks after treatment. We thus selected mice at 4 weeks post-STZ treatment for all the subsequent in vitro and electrophysiological experiments.

Effects of STZ-induced diabetes on islet morphology, α- and β-cell mass, and glucagon and insulin content. Confocal microscopy analysis of pancreas slices demonstrated a redistributed pattern of insulin (Fig. 2Ai and Bi [cells in red]) and glucagon (Fig. 2Aii and Bii [cells in yellow]) staining in islets of STZ-treated mice compared with controls. Control islets showed glucagon-labeled α cells resided along the islet periphery (Fig. 2Aii and Bii [cells in yellow]) and 2Aii [cells in both yellow and red]) and the larger mass of insulin-labeled β cells occupied the islet core (Fig. 2Ai and Ai, red). Total pancreatic α- and β-cell masses were determined by immunohistochemical quantification of insulin- and glucagon-positive staining areas (see RESEARCH DESIGN AND METHODS), normalized to entire pancreas cross-sectional tissue area; the resulting values were then multiplied by the wet pancreas weight of each mouse. Mean pancreas wet weights were similar (control 0.216 ± 0.006 g vs. STZ mice 0.251 ± 0.05 g; P = 0.43). The relative ratio of α cell to total pancreatic tissue area was also similar (control 0.0029 ± 0.0005 vs. STZ 0.0024 ± 0.0002; P = 0.36). However, the ratio of β cell to total pancreatic tissue area was reduced in STZ-treated mice (control 0.0152 ± 0.0017 vs. STZ 0.0048 ± 0.0006; P = 0.0005). STZ treatment reduced β-cell mass by 71% (Fig. 2C), but there was no difference in α-cell mass between STZ and control mice (Fig. 2D).

Surprisingly, total pancreatic glucagon and insulin content was severely reduced because of β-cell destruction (Fig. 2E) (control 3.02 ± 0.22 ng/μg vs. STZ 0.17 ± 0.02 ng/μg). Surprisingly, total pancreatic glucagon content per protein content in the STZ group was remarkably elevated to fourfold higher than in control mice (Fig. 2F) (control 4.59 ± 0.32 vs. STZ 18.71 ± 2.19 μg/μg).

STZ-treated GYY α cells are larger and have larger glucagon granules. The above results demonstrated that STZ induction of diabetes did not alter α-cell mass but increased glucagon content, which taken along with the increased plasma glucagon led us to postulate that each α cell in the STZ-treated mouse islet contains and releases more glucagon. We directly tested this hypothesis by two strategies: 1) single α-cell ΔIm induced by serial membrane depolarization and 2) ultrastructural analysis of
FIG. 3. α-Cell glucagon granule exocytosis in STZ-treated GYY mice. A: Mean α-cell capacitance ($\Delta C_m$) triggered by a train of 50 depolarizing pulses from −80 mV (60 ms) to 10 mV (40 ms). *$P < 0.05$; $n = 27$ cells from five control mice (●), $n = 30$ cells from four STZ mice (○). For recording conditions, see RESEARCH DESIGN AND METHODS. B: $\Delta C_m$ elicited by the 50th depolarizing pulses in A (*$P < 0.05$; $n = 27$ cells from five control mice, $n = 30$ cells from four STZ mice). C: Mean resting membrane capacitance of α cell, as a measure of the cell size. *$P < 0.05$; $n = 27$ cells from five control mice, $n = 30$ cells from four STZ mice. D and E: Representative electron micrographs of α cells of control (D) and STZ-treated (E) mice. D’ and E’: Magnified images of the white rectangles in D and E. F and G: Gaussian distribution curve of glucagon granule dense core diameters of control (F) and STZ (G).
α-cell glucagon granules. Since GYY mice express EYFP in pancreatic α cells, this allows α cells to be visualized within pancreas slices under a fluorescence microscope (Fig. 2Gb and Gd) and be accurately reached with the patch pipette (Fig. 2Ga and Gc). We performed electrophysiological characterizations on every recorded α cell as previously reported (6) to further confirm their identity.

A train of depolarizing pulses trigger ΔC_m in α cells due to Ca^{2+} influx and subsequent glucagon granule exocytotic fusion, as an indicator of α-cell secretion (6). Figure 3A shows mean ΔC_m in α cells of control and STZ mice in response to 50 pulses depolarizing from −80 to 10 mV, which was higher in STZ-treated mice α cells. Figure 3B summarizes the cumulative ΔC_m triggered at the 50th pulse to be higher in α cells of STZ-treated mice (control 12.2 ± 1.9 fF/μF vs. STZ 19.9 ± 3.2 fF/μF; P < 0.05). Interestingly, the resting C_m of α cells (Fig. 3C) measured before the depolarization stimuli, is proportional to cell membrane area, was also slightly increased in STZ α cells (5.33 ± 0.3 fF/μF) compared with control α cells (4.61 ± 0.18 fF/μF; P = 0.0496).

The increases in both evoked and resting C_m in α cells of STZ-treated mice suggest the possibility of an increase in the number and/or size of glucagon granules fusing with plasma membrane. To assess this possibility, we performed electron microscopy analysis of the islet α cells (Fig. 3D, control α cells; Fig. 3E, STZ-treated α cells). The corresponding enlarged views of the indicated areas (Fig. 3D’ and E’) show the glucagon dense core granules to be obviously larger in STZ α cells. Quantitative analysis shows that the mean diameter of granule dense core (Fig. 3F) was indeed larger in α cells of STZ-treated mice (228.50 ± 1.17 nm, N = 3,679 granules/32 cells; P < 0.0001) than control α cells (195.48 ± 0.94 nm, N = 2,642/18 cells). Analysis of granule distribution shows a shift in the overall sizes of glucagon granules of STZ-treated mice (Fig. 3G) compared with control α cells (Fig. 3F), with corresponding modes (peak of the curves relative to the vertical dotted line) of 209 ± 1.56 and 184 ± 1.5 nm, respectively. However, the number of glucagon granules per α cell determined as mean glucagon granules/cell area (Fig. 3H) was similar (control 3.0 ± 0.3 granules/μm² vs. STZ 2.3 ± 0.3 granules/μm²). If one assumes that dense core granules are perfect spheres and sizes of α cells are similar between the two groups, the volume of glucagon in α cells can be calculated by the equation V = 4/3 πr³, where r is the radius of the dense core. Accordingly, the volume of glucagon of an α cell of STZ-treated mice can be estimated to be 1.6 times larger than control α cells. Since resting C_m measurement (Fig. 3C) suggested an increased cell size in STZ-treated α cells, glucagon content in α cells of STZ-treated mice should be >1.6 times larger than control α cells.

Nonetheless, this increased glucagon content in glucagon granules may not be sufficient to fully account for the four times increase in pancreatic glucagon content in STZ-treated mice. Taken along with the similar sizes of α-cell mass, our results suggest that the success glucagon of α cell is likely also contributed by accumulation of glucagon content in other compartments (endoplasmic reticulum, Golgi, etc.), which in turn suggests an increased

in glucagon protein synthesis (which we currently don’t have the technical ability to determine).

**Voltage-gated K⁺ currents.** Voltage-gated K⁺ (Kᵥ) channels, shown to play a positive role in regulating glucagon secretion (17), were therefore assessed in α cells of control and STZ-treated mice (Fig. 4). In the control group (15 cells), a transient Kᵥ current became detectable when depolarizing membrane potential to −30 mV and above (Fig. 4A [control]); this current inactivated rapidly (−30 ms). Further depolarizing the membrane to −20 mV and higher voltages evoked an additional sustained Kᵥ component (indicated in Fig. 4A). In the STZ group (14 cells), α-cell transient Kᵥ current was notably suppressed (Fig. 4A [STZ]). Figure 4B summarized the transient Kᵥ current density, which was significantly suppressed in STZ α cells when membrane potential was depolarized to 20 mV (control 281.8 ± 20.2 pA/pF vs. STZ 241.8 ± 11.4 pA/pF; P < 0.05) and higher voltages. Figure 4C summarized Kᵥ-sustained current density, which was comparable between the two groups.

**Voltage-gated Ca^{2+} currents.** It is possible that α cells in STZ-treated mice might have larger Ca^{2+} influx to in part explain the larger C_m increase. We thus examined whether there is alteration in the properties of Ca^{2+} channels. In all the experiments, tetrodotoxin (0.1 μg/mL) was added in the bath solution to block voltage-gated Na⁺ current. A 300-ms ramp protocol running from −80 to 60 mV was applied to each α cell to trigger low voltage-activated (LVA) and high voltage-activated (HVA) Ca^{2+} currents. α cells from STZ-treated mice possessed LVA and HVA Ca^{2+} current density similar to that of control mouse α cells (Fig. 5A–H) (mean LVA control −3.14 ± 0.51 pA/pF vs. STZ −2.85 ± 0.25 pA/pF, P > 0.5; mean HVA control −7.10 ± 1.15 pA/pF vs. STZ −8.84 ± 0.82 pA/pF, P > 0.5; n = 8 control cells and 16 STZ cells). Since T-type current likely contributes to LVA Ca^{2+} currents, we added NiCl₂ (100 μmol/L) to block T-type Ca^{2+} channels (Fig. 5A and B [control] and Fig. 5E and F [STZ]). As anticipated, NiCl₂ reduced LVA Ca^{2+} current amplitude in α cells of controls from 3.14 ± 0.51 to 1.87 ± 0.42 pA/pF (Fig. 5A and B) (n = 6 cells) and that of STZ-treated mice from 2.51 ± 0.25 to 0.84 ± 0.29 pA/pF (Fig. 5E and F) (n = 11 cells). For confirmation of the HVA Ca^{2+} current component, CdCl₂, a broad-spectrum HVA Ca^{2+} channel blocker, was applied. The inward current component, peaked at 0–10 mV in both control (Fig. 5C and D [n = 6 cells]) and STZ (Fig. 5G and H [n = 6 cells]) cells, was completely abolished by CdCl₂ (200 μmol/L). Taken together, our results indicate that Ca^{2+} current in α cells is contributed by predominantly HVA channels, consistent with previous reports (18,19). Both current amplitudes of HVA- and T-type channels were not significantly altered by STZ treatment.

**Voltage-gated Na⁺ currents.** Current-voltage dependence of voltage-gated Na⁺ inward current was assessed by using Cs⁺-based tetraethylammonium-containing pipette solution to block Kᵥ currents (Fig. 6A). Na⁺ current can be elicited in every α cell of both control and STZ groups from −80-mV holding potential. Na⁺ inward current became detectable when depolarizing membrane potential to higher than −30 mV (Fig. 6A). Dotted lines indicate zero current level. The peaked Na⁺ current

(n = 2,642 granules from 18 cells of three control mice) and STZ-treated (G) (n = 3,679 granules from 32 cells of three STZ-treated mice) mice. Mean number of granules (H) and mean dense core diameter (I) of glucagon granules in α cells of control and STZ mice obtained from the same datasets in F and G, respectively. ***P < 0.001.

6 DIABETES diabetes.diabetesjournals.org
amplitudes were $-59.6 \pm 6.2$ pA/pF in controls and $-78.4 \pm 9.9$ pA/pF in the STZ group upon depolarizing to 0 mV (Fig. 6B and C). Na$^+$ channel I–V relationships of both control and STZ $\alpha$ cells exhibited a U-shaped voltage-dependent activation (Fig. 6B). Upon depolarizing to between $-20$ and 0 mV, $\alpha$ cells of the STZ group revealed significantly larger Na$^+$ current density than controls ($P < 0.05$). Peak Na$^+$ current was reached between $-10$ and 0 mV in both the STZ and control groups. Steady-state Na$^+$ channel inactivation was examined by a depolarizing pulse to 0 mV from a set of conditioning pulses between $-150$ and 0 mV in 10-mV increments (Fig. 6D). In both control and STZ-group $\alpha$ cells, steady-state Na$^+$ channel inactivation curve showed no difference; Na$^+$ channel half-inactivation potential ($V_{1/2}$) in the control and STZ groups was $-37.2$ and $-36.4$ mV, respectively (Fig. 6E).

Membrane electrical property of $\alpha$ cells in control and STZ-treated mice. Voltage-gated Na$^+$ and K$^+$ currents are important components contributing to $\alpha$-cell AP firing. We demonstrated that in the STZ-treated group, the Na$^+$ and K$^+$ current densities are, respectively, increased and decreased, and, thus, AP firing pattern in $\alpha$ cells could be subsequently altered. We performed current-clamp recordings to test this postulation.

After breaking the seal between pipette and cell membrane in voltage-clamp mode, current clamp mode was immediately switched to record resting membrane potential and regenerative AP firing. To confirm the $\alpha$-cell type in addition to their cellular EYFP (6), a short step protocol (<4.5 s) was executed in voltage-clamp mode to determine the Na$^+$-channel $V_{1/2}$.

The resting membrane potential in $\alpha$ cells was not significantly different between the two groups (control $-56.3 \pm 1.4$ mV vs. STZ $-54.0 \pm 2.9$ mV) (Fig. 7C). Robust AP firing was recorded in control (Fig. 7A) and STZ-treated mouse $\alpha$ cells (Fig. 7B). In control cells, AP fires spontaneously at a mean firing frequency of 0.68 ± 0.16 Hz (Fig. 7D); initiating at approximately $-45$ mV, giving rise to mean upstroke amplitude of 33.7 ± 1.8 mV, which then rapidly repolarized (Fig. 7A). In $\alpha$ cells of STZ-treated mice, AP firing frequency was significantly higher (2.33 ± 0.27 Hz; $P < 0.0001$) (Fig. 7B and D), along with higher mean AP amplitudes (control 33.7 ± 1.8 mV vs. STZ 54.2 ± 2.1 mV, $P < 0.0001$).

**DISCUSSION**

$\alpha$ Cells in healthy GYY mice expressed voltage-gated Na$^+$, Ca$^{2+}$, and K$^+$ currents and $\Delta C_m$ when depolarized. These electrophysiological properties are comparable with their background C57BL/6J and NMRI mice (6,10), validating GYY mice as an excellent model to study $\alpha$-cell physiology.
FIG. 5. Voltage-gated LVA and HVA Ca²⁺ current in α cells of STZ-treated GYY mice. Tetrodotoxin (TTX) (0.1 μg/mL) was added to block voltage-gated Na⁺ channels in all recordings. Representative I-V curves evoked by a 300-ms ramp protocol demonstrating LVA (A) and HVA (C) components in control cells. NiCl₂ (100 μmol/L) selectively blocked the LVA component, whereas CdCl₂ (200 μmol/L) blocked HVA components. The data are summarized in B and D. For recording conditions, see RESEARCH DESIGN AND METHODS. Representative I-V curves evoked by the ramp protocol demonstrating LVA (E) and HVA (G) components in STZ-treated cells. The data are summarized in F and H.
and pathophysiology. STZ-treated GYY mouse α cells exhibited hyperglucagonemia and consequent hyperglycemia. Hyperglucagonemia in STZ-treated GYY mice resulted from elevated total pancreatic glucagon content partly contained in the larger glucagon granules, which are expected to effect more stimulated-glucagon granule release. Since total pancreatic α-cell mass of STZ-treated GYY mice remained unchanged while total pancreatic glucagon content was fourfold elevated, it can be predicted that the larger glucagon granules containing some of the excess glucagon are exocytosed in response to every stimulus (i.e., low glucose) on each α cell, culminating in the observed hyperglucagonemia. This is evident by the higher Cm increase in STZ-treated mouse α cells when electrically depolarized. Our results in the STZ-treated mouse are similar to a recent report showing that genetically induced near-complete β-cell ablation led to increased α-cell glucagon content and also consequent hyperglucagonemia (20).

What are the electrical and/or cellular properties of α cells in STZ-treated mice that contributed to the observed hyperglucagonemia? First, AP firing frequency and amplitude in α cells of STZ-treated mice were more intensified, which would be expected to lead to more glucagon secretion. Whereas these changes in AP are expected to increase Ca2+ influx, we showed that whole-cell Ca2+ current was not different between STZ-treated and control mice. The increased AP could be attributed to changes in Na+ and K+ currents; in fact, STZ-treated mouse α cells exhibited larger Na+ current density and lower K+ current density.

**FIG. 6. Voltage-gated Na+ current in α cells of STZ-treated GYY mice.** A: Whole-cell Na+ current. Representative traces of Na+ current of a control α cell elicited by a 500-ms step depolarizing protocol from −80 to 40 mV in 10-mV increments at a holding potential of −80 mV (top panel). The magnified Na+ current in a larger time scale is shown in the inset box. Numbers in the box denote the applied voltage (mV). For recording conditions, see RESEARCH DESIGN AND METHODS. B: I–V relationship of the Na+ current. The peak Na+ current measured from the cells in the control and STZ groups is presented as the current density and plotted against the applied voltage. The current density was larger in the STZ group at the given voltage pulses. *Difference between the two groups was statistically significant (P < 0.05; control, N = 34 cells from six mice; STZ, N = 37 cells from four mice). C: Representative traces of Na+ current recorded from α cells in the control and STZ groups. The current was elicited by a step pulse from −80 to 0 mV. D: Steady-state inactivation properties of the Na+ channel. Representative current traces of a control cell were elicited by a standard two-pulse protocol (top panel). The magnified Na+ currents elicited by the test pulses are shown in the inset box. Numbers indicated by arrows in the box denote the test pulse voltage (mV). E: Steady-state Na+ current inactivation curves from control and STZ groups. The V1/2 is indicated by dashed lines. No differences were found between the control and STZ groups (P > 0.05; control, 34 cells from six mice; STZ, 37 cells from four mice). All of the recording were performed in Na+ 125 mmol/L in bath solution with Cs+ (135 mmol/L)-based pipette solution.
density (discussed below). Second, the higher $C_m$ increase in STZ-treated mouse $\alpha$ cells induced by serial membrane depolarization can be attributed to the larger glucagon granules exocytosing at the same $Ca^{2+}$ stimulus, thus emptying a larger cargo of glucagon than control mouse $\alpha$ cells. We showed that $K_V$ transient current within healthy $\alpha$ cells is rapidly activated and inactivated, which is similar to the A-type $K$ current we (19) and Rorsman and colleagues (21) have previously demonstrated in rodent $\alpha$ cells. Consistent with the consensus thinking, this would suggest that the reduced $K_V$ transient current in $\alpha$ cells of STZ-treated mice was likely the A-type $K$ current, contributing to the observed increased AP firing rate and amplitude (21,22). However, recent reports showed that the $K_V$ transient currents in both $\alpha$- and $\beta$ cells could also be contributed by large-conductance $Ca^{2+}$-activated voltage-gated $K^+ $ currents (BK currents) (7,23,24), and, hence, reduced BK currents could also contribute to increased secretion and potentiated AP amplitude (7,20,21,25). In STZ-treated mouse $\alpha$ cells, we noted the increased $Na^+$ current density coincided with an increase in AP amplitude. As expected (7,21), tetrodotoxin (an $Na^+$-channel blocker) inhibited glucagon secretion in both STZ and control pancreas slices (data not shown). These findings are consistent with the notion that $Na^+$ current influx-evoked AP trigger glucagon granule exocytosis.

What are the factors in STZ-treated mice that would cause suppression of $K_V$-transient current and enhancement

FIG. 7. $\alpha$-Cell membrane electrical activity of control and STZ-treated mice. A: A representative $\alpha$-cell membrane potential trace of a control mouse by current-clamp recording. For recording conditions, see RESEARCH DESIGN AND METHODS. A': A single AP profile in A shown in a larger time scale. Dashed line depicts zero current level in all graphs. B: A representative $\alpha$-cell membrane potential trace from an STZ-treated mouse. Note the larger AP amplitudes and more intense frequency of AP firing in the STZ group compared with the control (A). B': An AP profile in B shown in a larger time scale. C: Mean resting membrane potential recorded in $\alpha$ cells of control (black bar) and STZ-treated (white bar) mice. The data are presented as means ± SEM. ($P > 0.05; 19$ cells of seven control mice and $34$ cells of four STZ-treated mice.) D: Summary of $\alpha$-cell AP firing frequency between control and STZ-treated mice. The mean ± SEM firing frequency increased significantly in the STZ group ($15$ cells from seven control mice and $27$ cells from three STZ-treated mice, ***$P < 0.001$).
of Na\textsuperscript{+} current in \(\alpha\) cells? One possibility is the loss of paracrine regulation emanating from \(\beta\)-cell destruction, and these paracrine factors include insulin, \(\gamma\)-aminobutyric acid, and zinc (26–30) and possibly other factors. A second possibility is inflammatory cytokines secreted by cytotoxic T cells recruited during \(\beta\)-cell destruction induced by STZ, such as interleukin 1\(\beta\), interferon-\(\gamma\), and tumor necrosis factor-\(\alpha\) (26), which could conceivably activate or sensitize some \(\alpha\)-cell ion channels. In fact, several reports have shown that in colitis and ileitis animal models, release of inflammatory cytokine is associated with hyperexcitability of colonic dorsal root ganglion neurons, which were attributed to alterations in \(K_V\) and Na\textsuperscript{+} currents (31–35). These findings are consistent with our findings in \(\alpha\) cells in the STZ-induced diabetes mouse model. Diabetes development in the STZ-treated mouse model (8) or in patients with T1D (36) is associated with similar inflammatory processes in the islets (i.e., insulitis), wherein cytotoxic T cells are recruited and release inflammatory cytokines (26) that can be predicted to perturb ion channels in \(\alpha\) cells, perhaps in a manner similarly observed in this study.

The STZ-induced diabetes animal model in several respects mimics human T1D. STZ is transported into the \(\beta\) cell through Glut2 transporters, inducing cytotoxicity by oxidative damage and autoimmune reaction (8), including lymphocyte infiltration leading to insulitis and \(\beta\)-cell apoptosis (9). Because \(\alpha\) cells express only Glut1 or Glut5 transporters (37,38), they are likely protected from STZ-mediated destruction, hence, the normal \(\alpha\)-cell mass observed in this study. Furthermore, the complement of ion channel expression and functional properties of \(\alpha\) cells in STZ-treated mice was comparable with \(\alpha\) cells from control mice. Nevertheless, additional models of T1D, including noninflammatory (genetic ablation of \(\beta\) cells) (20) and autoimmune inflammatory (NOD mouse) models, should be tested in future studies to further validate the findings presented in this study and to explore the contributions of paracrine and inflammatory factors that may contribute to the perturbation of \(\alpha\) cells in T1D. Insights from such studies could lead to strategies to correct such perturbation, thereby normalizing \(\alpha\)-cell glucagon secretory responses (39).

ACKNOWLEDGMENTS

This study was mainly supported by the Canadian Diabetes Association (OG-3-10-3020-HG to H.Y.G.) and by a Canadian Institutes of Health Research doctoral award (CGD 76317 to Y.-C.H.). Z.-P.F. holds a Heart and Stroke Foundation New Investigator Award. This work is also supported by Juvenile Diabetes Research Fund Project Grant 2007-685 to P.G. and by Slovenian Research Agency Programme P3-0310-2334, grant J3-2290-2334, and MGP Partner Group Programme to M.R.

No potential conflicts of interest relevant to this article were reported.

Y.-C.H. performed all the experiments and data analysis, designed experiments, and wrote the manuscript. M.S.R. and Z.-P.F. contributed to the design of some experiments and to discussion and reviewed and edited the manuscript. N.K. provided technical assistance in glucagon secretion assay. P.L.H. and P.G. contributed to the discussion and provided the mice. H.Y.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

REFERENCES

3. Cryer PE. Hypoglycaemia: the limiting factor in the glycemic management of Type I and Type II diabetes. Diabetologia 2002;45:937–948
4. Butler PC, Rizza RA. Contribution to postprandial hyperglycemia and effect on initial splanchic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 1991;40:73–81
15. Gustavsson N, Wei SH, Hoang DN, et al. Synaptotagmin-7 is a principal Ca\textsuperscript{2+} sensor for Ca\textsuperscript{2+}-induced glucagon exocytosis in pancreas. J Physiol 2009;587:1169–1178
17. Spigelman AF, Dai X, MacDonald PE. Voltage-dependent K\textsuperscript{+} channels are positive regulators of alpha cell action potential generation and glucagon secretion in mice and humans. Diabetologia 2010;53:1917–1926
31. Ibeakanma C, Vanner S. TNFalpha is a key mediator of the pronociceptive effects of mucosal supernatant from human ulcerative colitis on colonic DRG neurons. Gut 2010;59:612–621
34. King DE, Macleod RJ, Vanner SJ. Trinitrobenzenesulphonic acid colitis alters Na1.8 channel expression in mouse dorsal root ganglia neurons. Neurogastroenterol Motil 2009;21:880–e64